Skip to content

LIMNW

Liminatus Pharma, Inc.

NASDAQ · Healthcare · Biotechnology · US

$0.04
+0.00%
Ask drillr

Year over year

Reported trailing growth

Revenue
—
EBITDA
—
EBIT
-52.8%
EPS
—
Free cash flow
—
Operating cash flow
—

Forward estimates

Based on analyst estimates

Revenue
—
EBITDA
—
EPS
—

Three-year CAGR

Revenue
—
EBITDA
—
EBIT
-2.1%
Net income
—
EPS
-7.5%
Free cash flow
—

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026